Tag: argx-113

September 17, 2018

Argenx Releases Positive Trial Results

On Monday, Argenx released positive clinical data from a proof-of-concept trial for its rare disease drug, efgartigimoid (ARGX-113).
September 17, 2018

argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

argenx (Nasdaq:ARGX) announced positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod (ARGX-113) in adult primary immune...